PRGN-2009
Gene therapy / editing
Evidence outlook · no controlled comparison
NCT05996523 · HPV-Associated Oropharyngeal Cancer
The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.
NCT05996523: The trial was not randomized or blinded and had no concurrent control arm; 26 participants were enrolled, with only 16 evaluable for the primary endpoint. Its primary endpoint was a laboratory immune biomarker rather than a clinical cancer outcome, and there was no formal comparator-based primary endpoint test, so the result is descriptive rather than controlled evidence for PRGN-2009.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04432597 NCT04432597 · HPV-Associated Oropharyngeal Cancer The study was a small, non-randomized, open-label trial without a placebo or active control arm, with participants assigned to sequential treatment cohorts. Its main phase II endpoint was an immune-cell biomarker rather than a clinical outcome, and there was no formal between-group primary endpoint comparison to test. Registry: NCT04432597 | 1/2 | Phase I: Recommended Phase II Dose of PRGN-2009 (Date treatment consent signed to date off study, approximately 18 months); Phase I: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term (Date treatment consent signed to date off study, an average of 6 months); Phase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment (Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment) 2022-11-22 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 2 more trials
NCT05996523 NCT05996523 · HPV-Associated Oropharyngeal Cancer The trial was not randomized or blinded and had no concurrent control arm; 26 participants were enrolled, with only 16 evaluable for the primary endpoint. Its primary endpoint was a laboratory immune biomarker rather than a clinical cancer outcome, and there was no formal comparator-based primary endpoint test, so the result is descriptive rather than controlled evidence for PRGN-2009. Registry: NCT05996523 | 2 | Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment. (Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment) 2025-05-22 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | Weak signal | link ↗ |
NCT06223568 NCT06223568 · HPV-Associated Oropharyngeal Cancer Registry: NCT06223568 | 2 | Determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC (6 months) 2028-01-10 | In progress: results expected 10 Jan 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow PRGN-2009 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.